JF Technology Berhad Reports Full Year 2025 Financial Results
August 30, 2025 - 01:37
JF Technology Berhad has announced its financial results for the full year 2025, showcasing a notable performance despite a slight decline in earnings per share. The company reported an earnings per share (EPS) of RM0.004, down from RM0.006 in the previous fiscal year of 2024.
In terms of revenue, JF Technology achieved RM44.8 million, reflecting a 7.7% increase compared to the prior year. This growth in revenue indicates the company’s resilience and ability to adapt to market conditions, even as it navigates through challenges that have impacted profitability.
The increase in revenue can be attributed to various factors, including enhanced product offerings and improved operational efficiencies. Management remains optimistic about future growth prospects, emphasizing their commitment to innovation and expansion in key markets.
Overall, while the EPS has seen a decline, the revenue growth signals a positive trajectory for JF Technology Berhad as it looks to build on this momentum in the coming years.
MORE NEWS
September 30, 2026 - 21:59
Micron Technology Tops Lofty Fiscal Q4 Goals, Guides Above ViewsMicron Technology exceeded analyst expectations for its fiscal fourth quarter, delivering results that outperformed even the most optimistic projections on Wall Street. The memory chip maker...
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...